Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 327

1.

Treatment and outcome of IG-MYC+ neoplasms with precursor B-cell phenotype in childhood and adolescence.

Herbrueggen H, Mueller S, Rohde J, Arias Padilla L, Moericke A, Attarbaschi A, Zimmermann M, Ratei R, Brueggemann M, Siebert R, Goehring G, Schlegelberger B, Bradtke J, Klapper W, Woessmann W, Burkhardt B.

Leukemia. 2019 Oct 14. doi: 10.1038/s41375-019-0606-6. [Epub ahead of print] No abstract available.

PMID:
31611629
2.

A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL.

Staiger AM, Altenbuchinger M, Ziepert M, Kohler C, Horn H, Huttner M, Hüttl KS, Glehr G, Klapper W, Szczepanowski M, Richter J, Stein H, Feller AC, Möller P, Hansmann ML, Poeschel V, Held G, Loeffler M, Schmitz N, Trümper L, Pukrop T, Rosenwald A, Ott G, Spang R; Emed Demonstrator Project; German High Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL).

Leukemia. 2019 Sep 17. doi: 10.1038/s41375-019-0573-y. [Epub ahead of print]

PMID:
31530861
3.

Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.

Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn MH, Natkunam Y, Calaminici M, Sander B, Baia M, Smith A, Painter D, Pham L, Zhao S, Ziepert M, Jordanova ES, Molina TJ, Kersten MJ, Kimby E, Klapper W, Raemaekers J, Schmitz N, Jardin F, Stevens WBC, Hoster E, Hagenbeek A, Gribben JG, Siebert R, Gascoyne RD, Scott DW, Gaulard P, Salles G, Burton C, de Jong D, Sehn LH, Maucort-Boulch D.

J Clin Oncol. 2019 Sep 9:JCO1900743. doi: 10.1200/JCO.19.00743. [Epub ahead of print]

PMID:
31498031
5.

Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration.

Tobin JWD, Keane C, Gunawardana J, Mollee P, Birch S, Hoang T, Lee J, Li L, Huang L, Murigneux V, Fink JL, Matigian N, Vari F, Francis S, Kridel R, Weigert O, Haebe S, Jurinovic V, Klapper W, Steidl C, Sehn LH, Law SC, Wykes MN, Gandhi MK.

J Clin Oncol. 2019 Aug 28:JCO1802365. doi: 10.1200/JCO.18.02365. [Epub ahead of print]

PMID:
31461379
6.

Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial: correlation with interim PET and outcome.

Richter J, Hüttmann A, Rekowski J, Schmitz C, Gärtner S, Rosenwald A, Hansmann ML, Hartmann S, Möller P, Wacker HH, Feller A, Thorns C, Müller S, Dührsen U, Klapper W.

Blood Cancer J. 2019 Aug 19;9(9):67. doi: 10.1038/s41408-019-0230-8. No abstract available.

7.

The impact of SOCS1 mutations in diffuse large B-cell lymphoma.

Mellert K, Martin M, Lennerz JK, Lüdeke M, Staiger AM, Kreuz M, Löffler M, Schmitz N, Trümper L, Feller AC, Hartmann S, Hansmann ML, Klapper W, Stein H, Rosenwald A, Ott G, Ziepert M, Möller P.

Br J Haematol. 2019 Aug 12. doi: 10.1111/bjh.16147. [Epub ahead of print]

PMID:
31407320
8.

The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma.

Hartmann S, Plütschow A, Mottok A, Bernd HW, Feller AC, Ott G, Cogliatti S, Fend F, Quintanilla-Martinez L, Stein H, Klapper W, Möller P, Rosenwald A, Engert A, Hansmann ML, Eichenauer DA.

Am J Hematol. 2019 Nov;94(11):1208-1213. doi: 10.1002/ajh.25607. Epub 2019 Aug 21.

PMID:
31396979
9.

Automated macrophage counting in DLBCL tissue samples: a ROF filter based approach.

Wagner M, Hänsel R, Reinke S, Richter J, Altenbuchinger M, Braumann UD, Spang R, Löffler M, Klapper W.

Biol Proced Online. 2019 Jul 1;21:13. doi: 10.1186/s12575-019-0098-9. eCollection 2019.

10.

Heterogeneous intracellular TRAIL-receptor distribution predicts poor outcome in breast cancer patients.

Heilmann T, Vondung F, Borzikowsky C, Szymczak S, Krüger S, Alkatout I, Wenners A, Bauer M, Klapper W, Röcken C, Maass N, von Karstedt S, Schem C, Trauzold A.

J Mol Med (Berl). 2019 Aug;97(8):1155-1167. doi: 10.1007/s00109-019-01805-w. Epub 2019 Jun 10.

PMID:
31183506
11.

Cryptic insertion of MYC exons 2 and 3 into the IGH locus detected by whole genome sequencing in a case of MYC-negative Burkitt lymphoma.

Wagener R, Bens S, Toprak UH, Seufert J, López C, Scholz I, Herbrueggen H, Oschlies I, Stilgenbauer S, Schlesner M, Klapper W, Burkhardt B, Siebert R.

Haematologica. 2019 May 9. pii: haematol.2018.208140. doi: 10.3324/haematol.2018.208140. [Epub ahead of print]

12.

Chromosomal gains of 12p and 1q are not associated with inferior outcome of pediatric and adolescent germ cell tumors.

Greimelmaier K, Calaminus G, Kristiansen G, Vokuhl C, Klapper W.

Pediatr Blood Cancer. 2019 Aug;66(8):e27777. doi: 10.1002/pbc.27777. Epub 2019 May 2.

PMID:
31045322
13.

A modular transcriptome map of mature B cell lymphomas.

Loeffler-Wirth H, Kreuz M, Hopp L, Arakelyan A, Haake A, Cogliatti SB, Feller AC, Hansmann ML, Lenze D, Möller P, Müller-Hermelink HK, Fortenbacher E, Willscher E, Ott G, Rosenwald A, Pott C, Schwaenen C, Trautmann H, Wessendorf S, Stein H, Szczepanowski M, Trümper L, Hummel M, Klapper W, Siebert R, Loeffler M, Binder H; German Cancer Aid consortium Molecular Mechanisms for Malignant Lymphoma.

Genome Med. 2019 Apr 30;11(1):27. doi: 10.1186/s13073-019-0637-7.

14.

MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma.

Hüllein J, Słabicki M, Rosolowski M, Jethwa A, Habringer S, Tomska K, Kurilov R, Lu J, Scheinost S, Wagener R, Huang Z, Lukas M, Yavorska O, Helfrich H, Scholtysik R, Bonneau K, Tedesco D, Küppers R, Klapper W, Pott C, Stilgenbauer S, Burkhardt B, Löffler M, Trümper LH, Hummel M, Brors B, Zapatka M, Siebert R, Kreuz M, Keller U, Huber W, Zenz T.

Cancer Res. 2019 Jun 15;79(12):3125-3138. doi: 10.1158/0008-5472.CAN-18-3438. Epub 2019 Apr 18.

PMID:
31000522
15.

[Hematological neoplasias as differential diagnoses of soft tissue tumors].

Koch K, Reddemann K, Klapper W, Oschlies I.

Pathologe. 2019 Jul;40(4):412-421. doi: 10.1007/s00292-019-0588-1. German.

PMID:
30941488
16.

Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma.

López C, Kleinheinz K, Aukema SM, Rohde M, Bernhart SH, Hübschmann D, Wagener R, Toprak UH, Raimondi F, Kreuz M, Waszak SM, Huang Z, Sieverling L, Paramasivam N, Seufert J, Sungalee S, Russell RB, Bausinger J, Kretzmer H, Ammerpohl O, Bergmann AK, Binder H, Borkhardt A, Brors B, Claviez A, Doose G, Feuerbach L, Haake A, Hansmann ML, Hoell J, Hummel M, Korbel JO, Lawerenz C, Lenze D, Radlwimmer B, Richter J, Rosenstiel P, Rosenwald A, Schilhabel MB, Stein H, Stilgenbauer S, Stadler PF, Szczepanowski M, Weniger MA, Zapatka M, Eils R, Lichter P, Loeffler M, Möller P, Trümper L, Klapper W; ICGC MMML-Seq Consortium, Hoffmann S, Küppers R, Burkhardt B, Schlesner M, Siebert R.

Nat Commun. 2019 Mar 29;10(1):1459. doi: 10.1038/s41467-019-08578-3.

17.

ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children.

Pearson ADJ, Scobie N, Norga K, Ligas F, Chiodin D, Burke A, Minard-Colin V, Adamson P, Marshall LV, Balakumaran A, Benettaib B, Bhargava P, Bollard CM, Bolotin E, Bomken S, Buechner J, Burkhardt B, Caron H, Copland C, Demolis P, Egorov A, Farhan M, Zugmaier G, Gross T, Horton-Taylor D, Klapper W, Lesa G, Marcus R, Miles RR, Nottage K, Pacaud L, Ricafort R, Schrappe M, Sterba J, Vezan R, Weiner S, Kim SY, Reaman G, Vassal G.

Eur J Cancer. 2019 Mar;110:74-85. doi: 10.1016/j.ejca.2019.01.013. Epub 2019 Feb 14.

PMID:
30772656
18.

Expression of ELF1, a lymphoid ETS domain-containing transcription factor, is recurrently lost in classical Hodgkin lymphoma.

Paczkowska J, Soloch N, Bodnar M, Kiwerska K, Janiszewska J, Vogt J, Domanowska E, Martin-Subero JI, Ammerpohl O, Klapper W, Marszalek A, Siebert R, Giefing M.

Br J Haematol. 2019 Apr;185(1):79-88. doi: 10.1111/bjh.15757. Epub 2019 Jan 25.

PMID:
30681722
19.

Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.

Hüttmann A, Rekowski J, Müller SP, Hertenstein B, Franzius C, Mesters R, Weckesser M, Kroschinsky F, Kotzerke J, Ganser A, Bengel FM, La Rosée P, Freesmeyer M, Höffkes HG, Hertel A, Behringer D, Prange-Krex G, Griesshammer M, Holzinger J, Wilop S, Krohn T, Raghavachar A, Maschmeyer G, Brink I, Schroers R, Gaska T, Bernhard H, Giagounidis A, Schütte J, Dienst A, Hautzel H, Naumann R, Klein A, Hahn D, Pöpperl G, Grube M, Marienhagen J, Schwarzer A, Kurch L, Höhler T, Steiniger H, Nückel H, Südhoff T, Römer W, Brinkmann M, Ose C, Alashkar F, Schmitz C, Dürig J, Hoelzer D, Jöckel KH, Klapper W, Dührsen U.

Ann Hematol. 2019 Apr;98(4):897-907. doi: 10.1007/s00277-018-3578-0. Epub 2019 Jan 4.

PMID:
30610279
20.

Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment.

Sasse S, Reddemann K, Diepstra A, Borchmann S, Oschlies I, Schnitter A, Engert A, Borchmann P, Klapper W.

Haematologica. 2019 Jan;104(1):e45-e46. doi: 10.3324/haematol.2018.207829. No abstract available.

21.

Non-leukemic pediatric mixed phenotype acute leukemia/lymphoma: Genomic characterization and clinical outcome in a prospective trial for pediatric lymphoblastic lymphoma.

Martin-Guerrero I, Salaverria I, Burkhardt B, Chassagne-Clement C, Szczepanowski M, Bens S, Klapper W, Zimmermann M, Kabickova E, Bertrand Y, Reiter A, Siebert R, Oschlies I.

Genes Chromosomes Cancer. 2019 Jun;58(6):365-372. doi: 10.1002/gcc.22726. Epub 2019 Jan 21.

PMID:
30578714
22.

The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma.

Wagener R, Seufert J, Raimondi F, Bens S, Kleinheinz K, Nagel I, Altmüller J, Thiele H, Hübschmann D, Kohler CW, Nürnberg P, Au-Yeung R, Burkhardt B, Horn H, Leoncini L, Jaffe ES, Ott G, Rymkiewicz G, Schlesner M, Russell RB, Klapper W, Siebert R.

Blood. 2019 Feb 28;133(9):962-966. doi: 10.1182/blood-2018-07-864025. Epub 2018 Dec 19.

PMID:
30567752
23.

Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial.

Kurch L, Hasenclever D, Kluge R, Georgi T, Tchavdarova L, Golombeck M, Sabri O, Eggert A, Brenner W, Sykora KW, Bengel FM, Rossig C, Körholz D, Schäfers M, Feuchtinger T, Bartenstein P, Ammann RA, Krause T, Urban C, Aigner R, Gattenlöhner S, Klapper W, Mauz-Körholz C.

Pediatr Blood Cancer. 2019 Mar;66(3):e27539. doi: 10.1002/pbc.27539. Epub 2018 Nov 14.

PMID:
30426671
24.

The translational science of hodgkin lymphoma.

Cirillo M, Reinke S, Klapper W, Borchmann S.

Br J Haematol. 2019 Jan;184(1):30-44. doi: 10.1111/bjh.15658. Epub 2018 Nov 12. Review.

PMID:
30417946
25.

CD38 is not expressed in pediatric ALK-positive anaplastic large cell lymphoma.

Au-Yeung RKH, Burkhardt B, Woessmann W, Klapper W.

Pediatr Blood Cancer. 2019 Mar;66(3):e27541. doi: 10.1002/pbc.27541. Epub 2018 Nov 8. No abstract available.

PMID:
30408331
26.

Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!

Dreyling M, Klapper W, Rule S.

Blood. 2018 Dec 27;132(26):2722-2729. doi: 10.1182/blood-2017-08-737502. Epub 2018 Nov 1. Review.

PMID:
30385481
27.

Simultaneous Occurrence of Rosai-Dorfman Disease and Nodal Marginal Zone Lymphoma in a Patient with Sjögren's Syndrome.

Gorodetskiy VR, Klapper W, Probatova NA, Vasilyev VI, Rozhnova EV.

Case Rep Hematol. 2018 Sep 16;2018:7930823. doi: 10.1155/2018/7930823. eCollection 2018.

28.

Macaca arctoides gammaherpesvirus 1 (strain herpesvirus Macaca arctoides): virus sequence, phylogeny and characterisation of virus-transformed macaque and rabbit cell lines.

Krumbholz A, Roempke J, Liehr T, Groth M, Meerbach A, Schacke M, Maschkowitz G, Fickenscher H, Klapper W, Sauerbrei A, Wutzler P, Zell R.

Med Microbiol Immunol. 2019 Feb;208(1):109-129. doi: 10.1007/s00430-018-0565-y. Epub 2018 Oct 5.

PMID:
30291474
29.

IG-MYC + neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas.

Wagener R, López C, Kleinheinz K, Bausinger J, Aukema SM, Nagel I, Toprak UH, Seufert J, Altmüller J, Thiele H, Schneider C, Kolarova J, Park J, Hübschmann D, Murga Penas EM, Drexler HG, Attarbaschi A, Hovland R, Kjeldsen E, Kneba M, Kontny U, de Leval L, Nürnberg P, Oschlies I, Oscier D, Schlegelberger B, Stilgenbauer S, Wössmann W, Schlesner M, Burkhardt B, Klapper W, Jaffe ES, Küppers R, Siebert R.

Blood. 2018 Nov 22;132(21):2280-2285. doi: 10.1182/blood-2018-03-842088. Epub 2018 Oct 3.

PMID:
30282799
30.

Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma.

Thurner L, Preuss KD, Bewarder M, Kemele M, Fadle N, Regitz E, Altmeyer S, Schormann C, Poeschel V, Ziepert M, Walter S, Roth P, Weller M, Szczepanowski M, Klapper W, Monoranu C, Rosenwald A, Möller P, Hartmann S, Hansmann ML, Mackensen A, Schäfer H, Schorb E, Illerhaus G, Buslei R, Bohle RM, Stilgenbauer S, Kim YJ, Pfreundschuh M.

Blood. 2018 Dec 27;132(26):2744-2753. doi: 10.1182/blood-2018-03-836932. Epub 2018 Sep 24.

PMID:
30249786
31.

T-Cell Clustering in Neoplastic Follicles of Follicular Lymphoma.

Schnotalle P, Koch K, Au-Yeung RKH, Reinke S, Winter K, Loeffler M, Braumann UD, Klapper W.

Cancer Microenviron. 2018 Dec;11(2-3):135-140. doi: 10.1007/s12307-018-0217-1. Epub 2018 Sep 11.

32.

Skin involvement by chronic lymphocytic leukaemia is frequently associated with unrelated neoplastic or inflammatory cutaneous disease and is not indicative of general disease progression.

Thiesen I, Wehkamp U, Brüggemann M, Ritgen M, Murga Penas EM, Klapper W, Oschlies I.

Br J Dermatol. 2019 Jan;180(1):227-228. doi: 10.1111/bjd.17135. Epub 2018 Oct 25. No abstract available.

PMID:
30183072
33.

Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles.

Hellmuth JC, Louissaint A Jr, Szczepanowski M, Haebe S, Pastore A, Alig S, Staiger AM, Hartmann S, Kridel R, Ducar MD, Koch P, Dreyling M, Hansmann ML, Ott G, Rosenwald A, Gascoyne RD, Weinstock DM, Hiddemann W, Klapper W, Weigert O.

Blood. 2018 Oct 18;132(16):1695-1702. doi: 10.1182/blood-2018-03-837252. Epub 2018 Aug 20.

PMID:
30126979
34.

Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network.

Rauert-Wunderlich H, Mottok A, Scott DW, Rimsza LM, Ott G, Klapper W, Unterhalt M, Kluin-Nelemans HC, Hermine O, Hartmann S, Thorns C, Rymkiewicz G, Holte H, Dreyling M, Hoster E, Rosenwald A.

Br J Haematol. 2019 Feb;184(4):616-624. doi: 10.1111/bjh.15519. Epub 2018 Aug 10.

PMID:
30095158
35.

Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment.

Sasse S, Reddemann K, Diepstra A, Oschlies I, Schnitter A, Borchmann S, Engert A, Borchmann P, Klapper W.

Haematologica. 2019 Jan;104(1):e21-e24. doi: 10.3324/haematol.2018.196279. Epub 2018 Aug 3. No abstract available.

36.

Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma.

De Smedt R, Peirs S, Morscio J, Matthijssens F, Roels J, Reunes L, Lintermans B, Goossens S, Lammens T, Van Roy N, Touzart A, Jenni S, Tsai YC, Lovisa F, Mussolin L, Serafin V, Van Nieuwerburgh F, Deforce D, Uyttebroeck A, Tousseyn T, Burkhardt B, Klapper W, De Moerloose B, Benoit Y, Macintyre E, Bourquin JP, Basso G, Accordi B, Bornhauser B, Meijerink J, Vandenberghe P, Van Vlierberghe P.

Haematologica. 2019 Jan;104(1):e17-e20. doi: 10.3324/haematol.2018.199257. Epub 2018 Aug 3. No abstract available.

37.

[Revised version of the 4th edition of the WHO classification of malignant lymphomas : What is new?]

Ott G, Klapper W, Feller AC, Hansmann ML, Möller P, Stein H, Rosenwald A, Fend F.

Pathologe. 2019 Mar;40(2):157-168. doi: 10.1007/s00292-018-0456-4. Review. German.

PMID:
30019203
38.

A B-cell-associated gene signature classification of diffuse large B-cell lymphoma by NanoString technology.

Michaelsen TY, Richter J, Brøndum RF, Klapper W, Johnsen HE, Albertsen M, Dybkær K, Bøgsted M.

Blood Adv. 2018 Jul 10;2(13):1542-1546. doi: 10.1182/bloodadvances.2018017988.

39.

t(11;14)-positive mantle cell lymphomas lacking cyclin D1 (CCND1) immunostaining because of a CCND1 mutation or exclusive expression of the CCND1b isoform.

Iaccarino I, Afify L, Aukema SM, Reddemann K, Schütt P, Flür M, Klapper W.

Haematologica. 2018 Sep;103(9):e432-e435. doi: 10.3324/haematol.2018.192435. Epub 2018 May 17. No abstract available.

40.

Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial.

Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, Berdel WE, Franzius C, Kroschinsky F, Weckesser M, Kofahl-Krause D, Bengel FM, Dürig J, Matschke J, Schmitz C, Pöppel T, Ose C, Brinkmann M, La Rosée P, Freesmeyer M, Hertel A, Höffkes HG, Behringer D, Prange-Krex G, Wilop S, Krohn T, Holzinger J, Griesshammer M, Giagounidis A, Raghavachar A, Maschmeyer G, Brink I, Bernhard H, Haberkorn U, Gaska T, Kurch L, van Assema DME, Klapper W, Hoelzer D, Geworski L, Jöckel KH, Scherag A, Bockisch A, Rekowski J, Hüttmann A; PETAL Trial Investigators.

J Clin Oncol. 2018 Jul 10;36(20):2024-2034. doi: 10.1200/JCO.2017.76.8093. Epub 2018 May 11.

PMID:
29750632
41.

Größenprogredienter Tumor an der lateralen Thoraxwand bei einem 14-jährigen Jungen.

Poch G, Vokuhl C, Klapper W, Erkens AS, Fölster-Holst R.

J Dtsch Dermatol Ges. 2018 May;16(5):640-643. doi: 10.1111/ddg.13428_g. No abstract available.

PMID:
29750465
42.

Round-robin test for the cell-of-origin classification of diffuse large B-cell lymphoma-a feasibility study using full slide staining.

Reinke S, Richter J, Fend F, Feller A, Hansmann ML, Hüttl K, Oschlies I, Ott G, Möller P, Rosenwald A, Stein H, Altenbuchinger M, Spang R, Klapper W.

Virchows Arch. 2018 Sep;473(3):341-349. doi: 10.1007/s00428-018-2367-4. Epub 2018 May 5.

PMID:
29730836
43.

[Aggressive B‑cell lymphomas : Recommendations from the German Panel of Reference Pathologists in the Competence Network on Malignant Lymphomas on diagnostic procedures according to the current WHO classification, update 2017].

Klapper W, Fend F, Feller A, Hansmann ML, Möller P, Stein H, Rosenwald A, Ott G.

Pathologe. 2019 Mar;40(2):152-156. doi: 10.1007/s00292-018-0440-z. Review. German.

PMID:
29666909
44.

Cooperative STAT/NF-κB signaling regulates lymphoma metabolic reprogramming and aberrant GOT2 expression.

Feist M, Schwarzfischer P, Heinrich P, Sun X, Kemper J, von Bonin F, Perez-Rubio P, Taruttis F, Rehberg T, Dettmer K, Gronwald W, Reinders J, Engelmann JC, Dudek J, Klapper W, Trümper L, Spang R, Oefner PJ, Kube D.

Nat Commun. 2018 Apr 17;9(1):1514. doi: 10.1038/s41467-018-03803-x.

45.

TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma.

Jethwa A, Słabicki M, Hüllein J, Jentzsch M, Dalal V, Rabe S, Wagner L, Walther T, Klapper W; MMML Network Project, Bohnenberger H, Rettel M, Lu J, Smits AH, Stein F, Savitski MM, Huber W, Aylon Y, Oren M, Zenz T.

Blood. 2018 Jun 21;131(25):2789-2802. doi: 10.1182/blood-2017-09-806679. Epub 2018 Apr 13.

PMID:
29653964
46.

Clinically defined subgroups of mycosis fungoides display differing histopathological features at initial biopsy.

Wehkamp U, Weichenthal M, Egberts F, Schwarz T, Klapper W, Oschlies I.

Leuk Lymphoma. 2018 Dec;59(12):2871-2879. doi: 10.1080/10428194.2018.1452218. Epub 2018 Apr 4.

PMID:
29616855
47.

Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2.

Horn H, Kohler C, Witzig R, Kreuz M, Leich E, Klapper W, Hummel M, Loeffler M, Trümper L, Spang R, Rosenwald A, Ott G; Molecular Mechanisms in Malignant Lymphomas (MMML) Network Project.

Haematologica. 2018 Jul;103(7):1182-1190. doi: 10.3324/haematol.2017.181024. Epub 2018 Mar 22.

48.

Enlarging tumor of the lateral chest wall in a 14-year-old boy.

Poch G, Vokuhl C, Klapper W, Erkens AS, Fölster-Holst R.

J Dtsch Dermatol Ges. 2018 May;16(5):640-643. doi: 10.1111/ddg.13428. Epub 2018 Jan 29. No abstract available.

PMID:
29377572
49.

S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 2: Therapie und Nachsorge (ICD10 C82 - C86).

Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Beyer M, Cozzio A, Eich HT, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke CD, Lamos C, Loquai C, Meiß F, Mestel D, Nashan D, Nicolay JP, Oschlies I, Schlaak M, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R.

J Dtsch Dermatol Ges. 2018 Jan;16(1):112-123. doi: 10.1111/ddg.13401_g. No abstract available.

PMID:
29314698
50.

S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 2: Treatment and Follow-up (ICD10 C82 - C86).

Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Beyer M, Cozzio A, Eich HT, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke CD, Lamos C, Loquai C, Meiß F, Mestel D, Nashan D, Nicolay JP, Oschlies I, Schlaak M, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R.

J Dtsch Dermatol Ges. 2018 Jan;16(1):112-122. doi: 10.1111/ddg.13401. Epub 2017 Dec 27. No abstract available.

PMID:
29280595

Supplemental Content

Loading ...
Support Center